Table 3.

The results of the univariate analyses and Cox multivariate analyses of factors predicting the OS (n = 52)

	Univariate		Multivariate
Variables	HR (95% CI)	p Value*	HR (95% CI)	p Value*
Age
(< 70 years vs. ≥70 years)	2.307 (0.93–5.76)	0.073
Sex
(Male vs. Female)	1.773 (1.20–2.61)	0.004	1.679 (1.13–2.50)	0.011
Prior nephrectomy
(yes vs. no)	1.190 (0.41–3.46)	0.749
ECOG PS
(0 vs. ≥1)	2.481 (1.14–5.38)	0.021
Treatment line of nivolumab
(2 vs. ≥3)	1.371 (0.62–3.03)	0.434
IMDC risk classification
(Favorable, Intermediate vs. Poor)	1.939 (0.73–5.16)	0.185
Number of Metastatic Organ site
(1,2 vs. ≥3)	1.799 (0.83–3.89)	0.135
CRP at baseline
(< 10 mg/L vs. ≥10 mg/L)	1.025 (0.47–2.23)	0.951
NLR at baseline
(< 3 vs. ≥3)	1.011 (0.46–2.23)	0.979
NLR at 4 weeks
(< 3 vs. ≥3)	2.857 (1.14–7.18)	0.026	2.734 (1.08–6.92)	0.034

^*Cox proportional hazards model

OS Overall survival; HR Hazard ratio; CI confidence interval; ECOG Eastern Cooperative Oncology Group; PS Performance status; IMDC International Metastatic Renal Cell Carcinoma Database Consortium; CRP C-reactive protein; NLR Neutrophil-to-lymphocyte ratio